Pure Global AI
NCT06061536Not yet recruiting

Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients.

A Randomized, Controlled, Open-label, Dose-exploration Study to Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients Who Have Not Received Antiviral Treatment Before.
Shanxi Kangbao Biological Product Co., Ltd.Phase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
HIV
Drug/Device/Intervention
Lipovirtide 10mg
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Shanxi Kangbao Biological Product Co., Ltd.
Timeline & enrollment
Phase
Phase 2
Start date
Oct 20, 2023
End date
Oct 30, 2024
Enrollment
64 participants
Primary outcome

HIV-1 RNA 50 copies/ml

Summary

A randomized, controlled, open-label, dose-exploration study to assess the effectiveness and
 safety of Lipovirtide combined with nucleoside drugs in HIV-infected patients who have not
 received antiviral treatment before.

ICD-10 classifications
Human immunodeficiency virus [HIV] diseaseHuman immunodeficiency virus [HIV] disease resulting in other conditionsHIV disease resulting in other viral infectionsUnspecified human immunodeficiency virus [HIV] diseaseHuman immunodeficiency virus [HIV] disease resulting in other specified diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06061536
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06061536 through Pure Global AI's free database. This Phase 2 trial is sponsored by Shanxi Kangbao Biological Product Co., Ltd. and is currently Not yet recruiting. The study focuses on HIV. Target enrollment is 64 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.